Using CRISPR/Cas9 to identify potential therapeutic targets in acute leukemia PDX cells

Binje Vick, PhD, Helmholtz Munich, Munich, Germany, comments on the potential of combining CRISPR screens with patient-derived xenograft (PDX) models to identify new therapeutic targets in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Dr Vick highlights a study that validated targets with single sgRNA and in vivo therapy trials. This approach holds promise for identifying new targets for treatment with available inhibitors. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео Using CRISPR/Cas9 to identify potential therapeutic targets in acute leukemia PDX cells канала VJHemOnc – Video Journal of Hematology & HemOnc
Теги: Speaker: Binje Vick, Institution: Helmholtz Munich, Event: ISAL 2025, Format: Interview, Subject: Acute Lymphoblastic Leukemia, Subject: Leukemia, Subject: Acute Myeloid Leukemia, Field: Treatment, Field: Disease Biology, ALL, AML, PDX models